 |
24 Diseases |  |
21 Trials |
|
21 Trials |  |
500 News |  |
| «123456789» |
- || Biomarker, Enrollment closed, Tumor microenvironment, Metastases: Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Jul 13, 2017
P1, N=114, Active, not recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting
- | Review, Journal: Investigational Janus kinase inhibitors in development for myelofibrosis. (Pubmed Central) - Jun 23, 2017
NS-018 and INCB039110, selective inhibitors of JAK2 and JAK1, respectively, are also discussed...Selective JAK1 inhibition alone is unlikely to succeed in myelofibrosis. In these circumstances, rational ruxolitinib-based combinations may represent the best way forward.
- |||||| itacitinib (INCB039110) / Incyte
Combination therapy: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Jun 22, 2017
P3, N=436, Recruiting, Sponsor: Incyte Corporation
In these circumstances, rational ruxolitinib-based combinations may represent the best way forward. Not yet recruiting --> Recruiting
- ||| itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Enrollment closed, Enrollment change: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - May 18, 2017
P1/2, N=87, Active, not recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=150 --> 87
- itacitinib (INCB039110) / Incyte, dezapelisib (INCB040093) / Incyte
Trial termination: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - May 10, 2017
P2, N=8, Terminated, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting | N=150 --> 87 Completed --> Terminated; A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.
- | Jakafi (ruxolitinib) / Novartis, Incyte, itacitinib (INCB039110) / Incyte
New P2 trial, Combination therapy: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis (clinicaltrials.gov) - May 9, 2017
P2, N=42, Not yet recruiting, Sponsor: Incyte Corporation
- |||||||||| itacitinib (INCB039110) / Incyte
Combination therapy: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - May 4, 2017
P3, N=436, Not yet recruiting, Sponsor: Incyte Corporation
- || dezapelisib (INCB040093) / Incyte
Trial primary completion date: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - Apr 19, 2017
P1, N=121, Active, not recruiting, Sponsor: Incyte Corporation
Completed --> Terminated; A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma. Trial primary completion date: May 2017 --> Dec 2017
- |||| itacitinib (INCB039110) / Incyte
Trial completion, Combination therapy, Metastases: Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2017
P1b/2, N=55, Completed, Sponsor: Incyte Corporation
Trial primary completion date: May 2017 --> Dec 2017 Active, not recruiting --> Completed
- ||| INCB052793 / Incyte
Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 19, 2017
P1/2, N=141, Recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Phase classification: P1a/1b --> P1/2 | N=282 --> 141 | Trial primary completion date: Jun 2018 --> May 2019
- || itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Biomarker, Tumor microenvironment, Metastases: Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 6, 2017
P1, N=140, Recruiting, Sponsor: Incyte Corporation
Phase classification: P1a/1b --> P1/2 | N=282 --> 141 | Trial primary completion date: Jun 2018 --> May 2019 N=78 --> 140 | Trial primary completion date: Jun 2017 --> Jun 2019
- || dezapelisib (INCB040093) / Incyte
Trial primary completion date: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - Jan 23, 2017
P1, N=121, Active, not recruiting, Sponsor: Incyte Corporation
N=78 --> 140 | Trial primary completion date: Jun 2017 --> Jun 2019 Trial primary completion date: Dec 2016 --> May 2017
- itacitinib (INCB039110) / Incyte, dezapelisib (INCB040093) / Incyte
Trial completion, Enrollment change, Trial primary completion date: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jan 23, 2017
P2, N=8, Completed, Sponsor: Incyte Corporation
Trial primary completion date: Dec 2016 --> May 2017 Active, not recruiting --> Completed | N=122 --> 8 | Trial primary completion date: Jan 2018 --> Jan 2017
- |||| itacitinib (INCB039110) / Incyte
Enrollment open, Combination therapy: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 13, 2017
P1/2, N=78, Recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed | N=122 --> 8 | Trial primary completion date: Jan 2018 --> Jan 2017 Not yet recruiting --> Recruiting
- || Biomarker, Trial primary completion date, Tumor microenvironment, Metastases: Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 6, 2017
P1, N=114, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- ||| itacitinib (INCB039110) / Incyte
Trial initiation date, Combination therapy: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 12, 2016
P1/2, N=78, Not yet recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Sep 2016 --> Dec 2016
- itacitinib (INCB039110) / Incyte
Enrollment change, Trial termination, Combination therapy: Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=9, Terminated, Sponsor: Incyte Corporation
Initiation date: Sep 2016 --> Dec 2016 N=150 --> 9 | Active, not recruiting --> Terminated; Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
- | itacitinib (INCB039110) / Incyte
Enrollment open, Combination therapy, Metastases: An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 3, 2016
P1/2, N=48, Recruiting, Sponsor: Incyte Corporation
N=150 --> 9 | Active, not recruiting --> Terminated; Sponsor decision to not initiate part 2 due to slow enrollment and competing trials. Not yet recruiting --> Recruiting
- | INCB052793 / Incyte
Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 20, 2016
P1a/1b, N=282, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Phase classification: P1 --> P1a/1b
- itacitinib (INCB039110) / Incyte
New P2 trial: Relieving Chronic Itch: Oral Medication (clinicaltrials.gov) - Sep 21, 2016
P2, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||| itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Enrollment change: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - Jul 20, 2016
P1/2, N=150, Recruiting, Sponsor: Incyte Corporation
Phase classification: P1 --> P1a/1b N=312 --> 150
- itacitinib (INCB039110) / Incyte
Combination therapy: Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD (clinicaltrials.gov) - Jul 1, 2016
P1, N=31, Active, not recruiting, Sponsor: Incyte Corporation
N=312 --> 150 Recruiting --> Active, not recruiting | N=20 --> 31
- ||||| itacitinib (INCB039110) / Incyte
New P1/2 trial, Combination therapy: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 3, 2016
P1/2, N=78, Not yet recruiting, Sponsor: Incyte Corporation
- || INCB052793 / Incyte
Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 22, 2016
P1, N=282, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting | N=20 --> 31 N=235 --> 282 | Trial primary completion date: Aug 2016 --> Jun 2018
- ||| itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Phase classification, Enrollment change, Trial primary completion date: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=312, Recruiting, Sponsor: Incyte Corporation
N=235 --> 282 | Trial primary completion date: Aug 2016 --> Jun 2018 Phase classification: P1 --> P1/2 | N=90 --> 312 | Trial primary completion date: Jan 2018 --> Jun 2018
- || itacitinib (INCB039110) / Incyte
Trial primary completion date, Combination therapy: Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 8, 2016
P2, N=150, Active, not recruiting, Sponsor: Incyte Corporation
Phase classification: P1 --> P1/2 | N=90 --> 312 | Trial primary completion date: Jan 2018 --> Jun 2018 Trial primary completion date: Oct 2016 --> Feb 2016
- ||| itacitinib (INCB039110) / Incyte
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Mar 4, 2016
P1b/2, N=53, Active, not recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Oct 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Feb 2016
- ||| itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Biomarker, Enrollment open, Tumor microenvironment, Metastases: Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 5, 2016
P1, N=78, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Feb 2016 Not yet recruiting --> Recruiting
- || dezapelisib (INCB040093) / Incyte
Enrollment closed: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - Jan 15, 2016
P1, N=121, Active, not recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| itacitinib (INCB039110) / Incyte, dezapelisib (INCB040093) / Incyte
Enrollment closed: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2016
P2, N=122, Active, not recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- itacitinib (INCB039110) / Incyte
Combination therapy: Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD (clinicaltrials.gov) - Dec 24, 2015
P1, N=20, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Biomarker, Enrollment open, Tumor microenvironment, Metastases: Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Dec 23, 2015
P1, N=114, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | itacitinib (INCB039110) / Incyte
Combination therapy: Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD (clinicaltrials.gov) - Nov 25, 2015
P1, N=20, Not yet recruiting, Sponsor: Incyte Corporation
- itacitinib (INCB039110) / Incyte
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations (clinicaltrials.gov) - Nov 17, 2015
P2, N=0, Withdrawn, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Sep 2015
- ||| Biomarker, New P1 trial, Tumor microenvironment, Metastases: Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors (clinicaltrials.gov) - Sep 24, 2015
P1, N=114, Not yet recruiting, Sponsor: Incyte Corporation
- ||| itacitinib (INCB039110) / Incyte
Phase classification, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 11, 2015
P1b/2, N=65, Recruiting, Sponsor: Incyte Corporation
N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Sep 2015 Phase classification: P1b --> P1b/2 | N=42 --> 65 | Trial primary completion date: Sep 2014 --> Jun 2016
- || INCB052793 / Incyte
Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 11, 2015
P1, N=235, Recruiting, Sponsor: Incyte Corporation
Phase classification: P1b --> P1b/2 | N=42 --> 65 | Trial primary completion date: Sep 2014 --> Jun 2016 N=105 --> 235
- ||||| itacitinib (INCB039110) / Incyte, dezapelisib (INCB040093) / Incyte
New P2 trial: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2015
P2, N=122, Not yet recruiting, Sponsor: Incyte Corporation
- ||| itacitinib (INCB039110) / Incyte
Enrollment closed, Combination therapy: Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=150, Active, not recruiting, Sponsor: Incyte Corporation
N=105 --> 235 Recruiting --> Active, not recruiting
- ||| itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - Apr 21, 2015
P1, N=90, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=40 --> 90 | Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Jul 2015 --> Jan 2018
- ||||| itacitinib (INCB039110) / Incyte
New P2 trial, Combination therapy: Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations (clinicaltrials.gov) - Feb 5, 2015
P2, N=150, Recruiting, Sponsor: Incyte Corporation
- || dezapelisib (INCB040093) / Incyte
Enrollment change, Trial primary completion date: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - Jan 18, 2015
P1, N=120, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting | N=40 --> 90 | Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Jul 2015 --> Jan 2018 N=90 --> 120 | Trial primary completion date: Dec 2014 --> Dec 2016
- ||| INCB052793 / Incyte
Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 17, 2014
P1, N=105, Recruiting, Sponsor: Incyte Corporation
- ||||| itacitinib (INCB039110) / Incyte
New P2 trial, Combination therapy: Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 10, 2014
P2, N=150, Recruiting, Sponsor: Incyte Corporation
- itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
Trial initiation date, Trial primary completion date: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - Sep 5, 2014
P1, N=40, Not yet recruiting, Sponsor: Incyte Corporation
N=90 --> 120 | Trial primary completion date: Dec 2014 --> Dec 2016 Initiation date: Feb 2014 --> Oct 2014 | Trial primary completion date: Nov 2014 --> Jul 2015
- || dezapelisib (INCB040093) / Incyte
Enrollment change: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - May 13, 2014
P1, N=90, Recruiting, Sponsor: Incyte Corporation
Initiation date: Feb 2014 --> Oct 2014 | Trial primary completion date: Nov 2014 --> Jul 2015 N=50 --> 90
- ||| itacitinib (INCB039110) / Incyte
Enrollment closed: An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 11, 2014
P2, N=125, Active, not recruiting, Sponsor: Incyte Corporation
N=50 --> 90 Recruiting --> Active, not recruiting
- |||| itacitinib (INCB039110) / Incyte
Trial completion: A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P2, N=106, Completed, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting Recruiting --> Completed
- | itacitinib (INCB039110) / Incyte, parsaclisib (INCB50465) / Incyte
New P1 trial: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) (clinicaltrials.gov) - Dec 19, 2013
P1, N=40, Not yet recruiting, Sponsor: Incyte Corporation
- | dezapelisib (INCB040093) / Incyte
New P1 trial: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) - Jul 21, 2013
P1, N=50, Recruiting, Sponsor: Incyte Corporation